Translating Regenerative Medicine to the Clinic

Dr Laurence is pursuing the pathophysiology of cardiovascular and skeletal abnormalities linked to HIV disease and its therapies at Weill Cornell. Dr Laurence is the editor-in-chief of Translational Medicine, which Elsevier co-publishes with the CSCTR.

Dr. Pedro Baptista is originally from Portugal, where he graduated from the School of Pharmacy of the University of Lisbon. He completed his doctoral dissertation at the Gulbenkian Ph.D. Program in Biomedicine. He is currently a Group Leader at the Health Research Institute of Aragon in Zaragoza, Spain and the founder of the Organ Bioengineering and Regenerative Medicine Laboratory at this institution. He is also an Assistant Professor at the Department of Biomedical and Aerospace Engineering at University Carlos III of Madrid, Spain. He is one of the founders and the Deputy Chairman of the European Association for the Study of the Liver Consortium for Regenerative Hepatology and currently the Deputy Secretary General and an elected Board Governor of the European Society for Artificial Organs. His current research focuses on creating bioengineered livers that can finally make the long-term transplantation of these lab-grown organs a reality.Dr. Pedro Baptista is originally from Portugal, where he graduated from the School of Pharmacy of the University of Lisbon. He completed his doctoral dissertation at the Gulbenkian Ph.D. Program in Biomedicine. He is currently a Group Leader at the Health Research Institute of Aragon in Zaragoza, Spain and the founder of the Organ Bioengineering and Regenerative Medicine Laboratory at this institution. He is also an Assistant Professor at the Department of Biomedical and Aerospace Engineering at University Carlos III of Madrid, Spain. He is one of the founders and the Deputy Chairman of the European Association for the Study of the Liver Consortium for Regenerative Hepatology and currently the Deputy Secretary General and an elected Board Governor of the European Society for Artificial Organs. His current research focuses on creating bioengineered livers that can finally make the long-term transplantation of these lab-grown organs a reality.

Anthony Atala, MD, is the G. Link Professor and Director of the Wake Forest Institute for Regenerative Medicine, and the W. Boyce Professor and Chair of Urology. Dr. Atala is a practicing surgeon and a researcher in the area of regenerative medicine. Fifteen applications of technologies developed in Dr. Atala's laboratory have been used clinically. He is Editor of 25 books and 3 journals. Dr. Atala has published over 800 journal articles and has received over 250 national and international patents. Dr. Atala was elected to the Institute of Medicine of the National Academies of Sciences, to the National Academy of Inventors as a Charter Fellow, and to the American Institute for Medical and Biological Engineering. Dr. Atala has led or served several national professional and government committees, including the National Institutes of Health working group on Cells and Developmental Biology, the National Institutes of Health Bioengineering Consortium, and the National Cancer Institute’s Advisory Board. He is a founding member of the Tissue Engineering Society, Regenerative Medicine Foundation, Regenerative Medicine Manufacturing Innovation Consortium, Regenerative Medicine Development Organization, and Regenerative Medicine Manufacturing Society.